Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAvalo Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$1.18 | -$1.18 | -$1.18 |
| Q2 2024 | 1 | -$6.70 | -$6.70 | -$6.70 |
| Q3 2024 | 1 | -$1.19 | -$1.19 | -$1.19 |
| Q4 2024 | 2 | -$1.45 | -$1.38 | -$1.42 |
| Q1 2025 | 1 | -$1.21 | -$1.21 | -$1.21 |
| Q2 2025 | 1 | -$1.22 | -$1.22 | -$1.22 |
| Q3 2025 | 1 | -$1.25 | -$1.25 | -$1.25 |
| Q4 2025 | 1 | -$1.25 | -$1.25 | -$1.25 |
Avalo Therapeutics, Inc. Earnings Date And Information
Avalo Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-2.83 earnings per share for the quarter, missing analysts' consensus estimates of $-1.19 by $1.64. The company had revenue of 249,000 for the quarter and had revenue of 1.92 M for the year. Avalo Therapeutics, Inc. has generated $-114 earnings per share over the last year ($-113.58 diluted earnings per share) and currently has a price-to-earnings ratio of -9.1. Avalo Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based on prior year's report dates.
Avalo Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$1.19 | $2.83 | 4.02 | $300,000 | $249,000 |
| 08/12/2024 | Q2 2024 | -$6.70 | $4.21 | 10.91 | $300,000 | $0 |
| 07/11/2024 | Q1 2024 | -$141.14 | $0 | |||
| 03/29/2024 | Q4 2023 | -$4.80 | -$10.20 | -5.4 | $571,000 | |
| 11/09/2023 | Q3 2023 | -$261.90 | -$26.83 | 235.07 | $1.00 M | $236,000 |
| 08/03/2023 | Q2 2023 | -$214.29 | -$140.73 | 73.56 | $1.00 M | $643,000 |
| 05/04/2023 | Q1 2023 | -$230.95 | -$203.81 | 27.14 | $475,000 | |
| 03/29/2023 | Q4 2022 | -$123.81 | -$249.99 | -126.18 | $896,000 | |
| 11/07/2022 | Q3 2022 | -$245.24 | $81.38 | 326.62 | $1.26 M | $14.95 M |
| 08/04/2022 | Q2 2022 | -$428.57 | -$331.55 | 97.02 | $1.19 M | $1.03 M |
| 05/05/2022 | Q1 2022 | -$400.16 | -$563.03 | -162.87 | $1.17 M | |
| 03/02/2022 | Q4 2021 | -$1.90 | -$484.39 | -482.49 | $219,000 | |
| 11/09/2021 | Q3 2021 | -$543.07 | -$498.52 | 44.55 | $1.12 M | $1.35 M |
| 08/02/2021 | Q2 2021 | -$2.04 | -$453.56 | -451.52 | $333,333 | $3.36 M |
| 05/13/2021 | Q1 2021 | -$2.32 | -$931.42 | -929.1 | $473,000 | |
| 03/08/2021 | Q4 2020 | -$1.80 | -$554.31 | -552.51 | $1.50 M | |
| 11/09/2020 | Q3 2020 | -$1.14 | -$477.43 | -476.29 | $1.50 M | $1.11 M |
| 08/06/2020 | Q2 2020 | -$1.26 | -$553.60 | -552.34 | $2.25 M | $1.34 M |
| 05/07/2020 | Q1 2020 | -$1.22 | -$977.46 | -976.24 | $2.75 M | |
| 03/11/2020 | Q4 2019 | $0.84 | -$277.62 | -278.46 | $-8,723,772 |
Avalo Therapeutics, Inc. Earnings: FAQ's
When is Avalo Therapeutics, Inc.'s earnings date?
Avalo Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based off last year's report dates.
How can I listen to Avalo Therapeutics, Inc.'s earnings conference
call?
The conference call for Avalo Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Avalo Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Avalo Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Avalo Therapeutics, Inc. generate each year?
Avalo Therapeutics, Inc. (:AVTX) has a recorded annual revenue of $1.92 M.
How much profit does Avalo Therapeutics, Inc. generate each year?
Avalo Therapeutics, Inc. (:AVTX) has a recorded net income of $1.92 M. Avalo Therapeutics, Inc. has generated $-113.58 earnings per share over the last four quarters.
What is Avalo Therapeutics, Inc.'s price-to-earnings ratio?
Avalo Therapeutics, Inc. (:AVTX) has a price-to-earnings ratio of -9.1 and price/earnings-to-growth ratio is -0.51.